Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01206933 · ClinicalTrials.gov registry record
The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System
A clinical trial, sponsored by George Washington University.
- Completed
- Registry status
- 20
- Enrollment target
NCT01206933: Completed study, sponsored by George Washington University.
NCT01206933 is a clinical trial that has completed, run by George Washington University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01206933 has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infection (HIV/HCV) have a more rapid and progressive course of HCV infection, leading to fatty infiltration of the liver and cirrhosis.
Primary Outcome
The validation that HIV Tat protein is a potent inducer of HCV in dual infected patients will likely lead to anti-tat therapy to manage HCV patients for whom treatment options are rather limited.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2010-07 |
| Est. Completion | 2015-06 |
What the finished NCT01206933 record still lists
NCT01206933 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01206933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01206933 about?
NCT01206933 is a clinical study titled "The Effect of HIV Tat Protein on HCV Replication in an In-vitro Model System". Investigators in the Division of Infectious Diseases and the Departments of Biochemistry and Molecular Biology of The George Washington University Medical Center are carrying out a research study to determine why patients with Human Immunodeficiency Virus (HIV) and Hepatitis C virus (HCV) co-infecti...
What is the current status of trial NCT01206933?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2010-07. Estimated completion is 2015-06.
Who is sponsoring clinical trial NCT01206933?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia